MorphoSys
MorphoSys AG was a German biopharmaceutical company founded in 1992 that discovered and developed fully human antibody therapeutics for hematology-oncology indications, serving cancer patients globally through healthcare providers. It was acquired by Novartis in 2024 for approximately €2.7 billion.
- Company typePublic
- Founded1992
- HeadquartersPlanegg, Germany
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What MorphoSys does
MorphoSys AG was a German biopharmaceutical company founded in 1992 and headquartered in Planegg, Germany, focused on the discovery and development of fully human antibody therapeutics for cancer. The company operated proprietary antibody discovery technology platforms and built a pipeline of investigational drugs targeting hematological malignancies and solid tumors, with a concentrated focus on hematology-oncology indications including myelofibrosis. Following the 2021 acquisition of Constellation Pharmaceuticals for $1.7 billion (financed in part through a Royalty Pharma partnership of up to $350 million), MorphoSys incorporated late-stage assets such as pelabresib into its pipeline, strengthening its position in rare blood cancers.
The company's revenue model centered on development and eventual commercialization of therapeutic antibodies through regulatory-approved pathways in Europe, Asia, and the United States, selling via traditional pharmaceutical distribution channels to hospitals, specialty oncology practices, and healthcare professionals serving hematology-oncology patients. It operated with 501–1,000 employees and raised capital through a mix of public equity and a December 2023 post-IPO capital increase of approximately €102.7 million at €30.00 per share.
In 2024, MorphoSys was acquired by Novartis AG for approximately €2.7 billion (~$2.9 billion), and the company was delisted from public markets and integrated into Novartis's hematology portfolio as a wholly owned subsidiary. The company therefore no longer operates as an independent commercial entity.
MorphoSys firmographics
Firmographics- Name
- MorphoSys
- Legal name
- MorphoSys AG
- Website
- https://morphosys.com
- Company type
- Public
- Founded year
- 1992
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- MorphoSys AG was a German biopharmaceutical company founded in 1992 that discovered and developed fully human antibody therapeutics for hematology-oncology indications, serving cancer patients globally through healthcare providers. It was acquired by Novartis in 2024 for approximately €2.7 billion.
- Ownership category
- akta.pro rank
MorphoSys industry classification
Industry- Product category
- Biopharmaceutical Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where MorphoSys is headquartered
LocationHeadquarters
- HQ city
- Planegg
- HQ country
- Germany
- HQ region
- Europe
Markets served
MorphoSys business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
MorphoSys product offering
Product offeringCore offering
MorphoSys AG discovers and develops fully human antibody therapeutics for the treatment of cancer, with a primary focus on hematology-oncology and rare hematologic malignancies. Its portfolio includes proprietary antibody drug candidates and late-stage assets such as pelabresib for myelofibrosis, acquired through the 2021 purchase of Constellation Pharmaceuticals for $1.7 billion. Following its 2024 acquisition by Novartis AG, MorphoSys's products are commercialized as part of Novartis's hematology portfolio across Europe, Asia, and the United States.
Product overview
MorphoSys AG is a German biotech company engaged in the discovery and development of novel antibodies for the treatment of cancer. The company has operated in the hematology-oncology space, developing therapeutic candidates for the treatment of hematological diseases and solid tumors. MorphoSys's portfolio included proprietary technology platforms for antibody discovery and a pipeline of investigational drugs. The company was acquired by Novartis in 2024 for approximately $2.9 billion, making it a wholly owned subsidiary and expanding Novartis's hematology portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- Pelabresib (BET inhibitor) Pelabresib is a BET (bromodomain and extraterminal) inhibitor therapeutic candidate indicated for myelofibrosis and related hematologic malignancies. It is a late-stage oncology drug candidate acquired from Constellation Pharmaceuticals and intended for patients with rare blood cancers where treatment options are limited.
Companies that use MorphoSys
Customer profileSegments2 records
Ideal customer profiles1 record
MorphoSys technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MorphoSys partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Tango TherapeuticsminorMalte Peters, previously served as Chief Research and Development Officer at MorphoSys AG, joined Tango Therapeutics as President and CEO. This represents a personnel connection rather than a formal partnership.
Scale indicators11 records
Recent moves8 records
Expansion highlights4 records
MorphoSys competitors and assessment
Company assessmentDirect peers
- MacroGenics:
- Genmab: Genmab is a Danish antibody therapeutics company specializing in fully human and humanized monoclonal antibodies for cancer. Direct peer to MorphoSys in antibody platform technology, hematology-oncology focus, and European biotech origin.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron is a large-cap biotech with a proprietary VelocImmune antibody platform and a diversified oncology/immunology pipeline including bispecifics competing in DLBCL. Broader incumbent with antibody discovery capabilities comparable to MorphoSys's HuCAL platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
MorphoSys social profiles
Digital presenceMorphoSys financial estimates
Financial estimateRevenue estimate
Valuation estimate
MorphoSys leadership team
Management profileNumber of profiles
Profiles4 records
MorphoSys subsidiaries and ownership
Company hierarchySubsidiaries1 record
MorphoSys funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MorphoSys M&A and investment
M&A and investmentM&A3 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MorphoSys
What does MorphoSys do?
MorphoSys AG discovers and develops fully human antibody therapeutics for the treatment of cancer, with a primary focus on hematology-oncology and rare hematologic malignancies. Its portfolio includes proprietary antibody drug candidates and late-stage assets such as pelabresib for myelofibrosis, acquired through the 2021 purchase of Constellation Pharmaceuticals for $1.7 billion. Following its 2024 acquisition by Novartis AG, MorphoSys's products are commercialized as part of Novartis's hematology portfolio across Europe, Asia, and the United States.
Is MorphoSys a public or private company?
MorphoSys is a public company. It is classified as corporate owned and is currently acquired.
When was MorphoSys founded?
MorphoSys was founded in 1992. It employs 501 to 1,000 people.
Where is MorphoSys based?
MorphoSys is headquartered in Planegg, Germany, in the Europe region.
Who are MorphoSys's main competitors?
Direct peers on record are MacroGenics and Genmab. Regeneron Pharmaceuticals is listed as a broad incumbent.
Does MorphoSys have an API?
No public API is recorded for MorphoSys.
What industry is MorphoSys in?
MorphoSys's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.